ArticleACS omega2025
Application of ES-DMA-CPC for Comprehensive Molecular Profiling in Hemodialysis: A Focus on β2-Microglobulin.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulation of middle- and large-sized uremic toxins has been associated with frailty and mortality in hemodialysis patients. In clinical practice, immunological methods are used for the quantification of those toxins; however, the requirement for expensive antibodies and chemicals limits their clinical application. In this study, we propose an antibody-free analytical method, an electrospray differential mobility analyzer coupled with a condensation particle counter (ES-DMA-CPC), for the analysis of middle- and large-sized uremic toxins in spent dialysate collected from hemodialysis patients. When applied to the analysis of the middle-sized uremic toxin β2-microglobulin, the spent dialysate-based ES-DMA-CPC method shows a high correlation with the current gold standard, enzyme-linked immunosorbent assay, as well as the serum-based immunoturbidimetry. Additionally, ES-DMS-CPC simultaneously provides concentrations of molecules with a molecular weight range of 2.5-180 kDa, which offers possibilities for the study of the molecular profile in hemodialysis patients and for the quantification of the practical sieving performance of the dialyzer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.